Biomarkers commonly tracked during peptide protocols
Peptide protocols don’t exist in a vacuum. A baseline lab panel tells the clinician where you’re starting from — and follow-up labs tell both of you whether the protocol is doing what it’s supposed to.
TL;DR
- Baseline labs before starting a peptide protocol are standard practice — they establish the reference point every follow-up is measured against.
- The specific markers ordered depend on the protocol: GH-secretagogue protocols call for IGF-1; metabolic protocols add A1C and fasting glucose; men’s protocols include testosterone and SHBG.
- Lab cadence is typically baseline → 8–12 weeks → annual; clinicians adjust based on findings.
What it is
A biomarker is a measurable biological indicator — a number derived from a blood draw, urine sample, or imaging study — that provides objective information about physiology. In the context of peptide protocols, biomarkers serve two functions: they establish whether a protocol is contraindicated (e.g., a pre-existing IGF-1 elevation before starting a GH-secretagogue), and they track the protocol’s downstream effects over time. The Endocrine Society’s clinical practice guidelines on adult growth hormone deficiency and hypogonadism both emphasize baseline and follow-up laboratory assessment as foundational to safe prescribing (Endocrine Society Clinical Practice Guidelines, 2019).
How it works
The markers most commonly ordered fall into a few categories:
GH-secretagogue protocols (e.g., sermorelin, CJC-1295/ipamorelin, tesamorelin):
- IGF-1 (insulin-like growth factor 1) — the primary downstream marker of GH axis activity
- Fasting glucose and A1C — GH-axis stimulation can affect insulin sensitivity
Metabolic and GLP-1 protocols:
- A1C and fasting glucose — baseline and follow-up to track glycemic change
- Lipid panel (total cholesterol, LDL, HDL, triglycerides)
- Comprehensive metabolic panel (CMP) — liver and kidney function
Men’s health protocols:
- Total testosterone and free testosterone
- SHBG (sex hormone-binding globulin) — determines bioavailable testosterone
- Sensitive estradiol (E2) — estrogen balance
- LH and FSH — when evaluating pituitary-gonadal axis
General baseline for most protocols:
- CBC (complete blood count) — baseline hematology
- CMP — metabolic safety screen
- Lipid panel
Who asks about it
People who’ve received a prescription and a lab order simultaneously often have questions about which tests map to which part of the protocol, and how often they’ll need to repeat them. This question also comes from people in the research phase who want to understand what clinical oversight looks like in practice.
What the research says
The Endocrine Society recommends serum IGF-1 measurement every 6 months during GH-axis therapy until stable, then annually — with dose adjustments guided by IGF-1 levels remaining within the age- and sex-adjusted normal range (Endocrine Society GH Deficiency Guideline, 2019). For testosterone protocols, the same society recommends testosterone measurement at 3 months, then annually once stable.
What to know before considering it
Lab frequency and which panels are ordered are clinical decisions — they’re not standardized across all protocols or all patients. A prescribing clinician reviews your specific history, current medications, and goals before determining the appropriate panel. Off-protocol lab interpretation — reading your own numbers without clinical context — can lead to misinterpretation.
The Halftime POV
Having a lab baseline before starting any protocol is one of the clearest markers of a rigorous clinical program versus an informal one. Numbers you collect before you start are the only honest way to evaluate whether anything changed afterward. The inconvenience of a blood draw is not a reason to skip that step.
Related reading:
FAQ
Q: What labs are typically ordered before starting a peptide protocol? A: A standard pre-protocol panel includes IGF-1 (for GH-axis assessment), CBC (complete blood count), CMP (comprehensive metabolic panel), lipid panel, thyroid panel (TSH, free T3/T4), and testosterone with SHBG where relevant. The specific panel depends on the protocol type — a GLP-1 protocol emphasizes metabolic markers; a GH-axis protocol emphasizes IGF-1 and pituitary function.
Q: Why is IGF-1 tested before a GH-axis peptide protocol? A: IGF-1 is the primary clinically measurable proxy for GH-axis activity. Baseline IGF-1 establishes where you are before the protocol and allows a clinician to monitor response over time. Protocols should not be initiated without a baseline, and follow-up testing at 3 months helps assess whether the protocol is having the intended effect.
Q: How often should labs be repeated during a peptide protocol? A: The typical monitoring cadence is a follow-up panel at 3 months after initiation, then every 6 months for ongoing protocols. Specific markers are re-tested based on which peptide is being used — IGF-1 for GH-axis compounds, A1C for GLP-1 protocols, hormone panels for testosterone-adjacent protocols. Your clinician determines the appropriate schedule.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Endocrine Society Clinical Practice Guidelines — endocrine.org, 2019
- Yuen KCJ et al., “American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults” — Endocrine Practice, 2019
- Bhasin S et al., “Testosterone Therapy in Men with Hypogonadism: Endocrine Society Clinical Practice Guideline” — JCEM, 2018
